ABSTRACT
Diagnosis of genetic diseases has taken tremendous steps forward since the human genome project and technical advancements such as next generation sequencing. However, in the past years it has become evident that the classical “one gene – one phenotype” model is insufficient to encompass the intricacies of human genetics. Examples are emerging that variants in a gene can cause quite diverging phenotypes depending on the specific location in the gene or on the specific type of variant. In the era of precision medicine this is important knowledge, both when interpreting genomic data, but also when designing treatment strategies.
Gain-of-function variants in GFAP leads to protein aggregation and is the cause of the severe neurodegenerative disorder Alexander Disease (AxD), while loss of GFAP function has been considered benign. Here, we report a loss-of-function variant in GFAP as the cause of optico-retinal dysplasia and vision impairment in a six-generation family.
Whole genome sequencing analysis of family members with gliosis of the optic nerve head and visual impairment revealed a frameshift variant in GFAP (c.928dup, p.(Met310Asnfs*113)) segregating with disease. Analysis of human embryonic tissues revealed strong expression of GFAP in retinal neural progenitors. A zebrafish model verified that c.928dup does not result in extensive GFAP protein aggregation and zebrafish gfap loss-of-function mutants showed vision impairment and retinal dysplasia, characterized by a significant loss of Müller glia cells and photoreceptor cells.
Our findings show how different mutational mechanisms can cause diverging phenotypes and reveal a novel function of GFAP in human eye development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by grants from the Velux Foundation, the Novo Nordisk Foundation and the Carlsberg Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Committee on Health Research Ethics, Denmark gave ethical approval for the clinical and genetic study of patients (journal number 1301394). Danish Regional Committee on Health Research Ethics gave ethical approval for analysis of human embryos and fetuses (KF V.100.1735/90) and (KF 11 2006 4838). All zebrafish experiments and animal handling procedures were approved and conducted under licenses from the Danish Animal Experiments Inspectorate (Protocol code: P18-120/P20-387).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript was significantly revised and new data added.
Data Availability
Individual genome sequencing data cannot be shared due to concerns over patient privacy. Other data generated or analyzed during this study are included in the main paper or its additional files.
